Case/noncase analysis of the FDA Adverse Events Reporting System suggests higher reporting odds of photosensitivity and esophageal symptoms for sarecycline than of those for other tetracyclines

Abstract

To the Editor: Tetracyclines have been widely used since their initial approval by the US Food and Drug Administration in 1957. 1 Henehan M. Montuno M. De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad Dermatol Venereol. 2017; 31: 1800-1808 Google Scholar The newest of these agents, sarecycline, was approved by the Food and Drug Administration in 2018 for the treatment of nonnodular moderate-to-severe acne vulgaris. To date, the reporting odds ratios (RORs) of adverse events (AEs) with tetracyclines have not been compared with those of AEs with sarecycline. 2 Lebrun-Vignes B. Kreft-Jais C. Castot A. Chosidow O. French Network of Regional Centers of PharmacovigilanceComparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012; 166: 1333-1341 Google Scholar Therefore, we used the FDA Adverse Event Reporting System to perform case/noncase analyses and investigate the associations between exposure to tetracyclines and the development of AEs.